Wire · opportunities
Artificial Intelligence in Liver and Heart Disease Treatment
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 October 2026 · Fusion42 review
Artificial intelligence is accelerating drug discovery for complex liver and heart diseases by identifying disease mechanisms and improving target selection. The AstraZeneca and Insitro collaboration exemplifies AI's growing role in developing treatments for metabolic dysfunction-associated steatohepatitis and cardiomyopathies.
This Wire brief sits within Fusion42's coverage of AI Frontier Models, Drug Discovery and Biotech, and 2 sources have reported it between 15 Oct 2026 and 22 Oct 2026.
◆ ◆ The Wire takeaway
You can now use AI models to prioritise drug candidates for liver and heart diseases, cutting early-stage research time. Established pharma investing heavily in AI makes biotech collaborations a new avenue for competitive advantage.
◆ Coverage
2 sources · first reported 15 Oct 2026 · latest 22 Oct 2026
◆ Related on Wire
◆ Topics